The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 20 April 2026•Updated 20 April 2026•

1 min read

Clearmind Medicine Reports Positive Safety Results in AUD Clinical Trial

Key Facts

1The proprietary drug candidate CMND-100 met its primary safety endpoint in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD).

about 1 month ago

Version History

1 additional source confirmed this story

Version 2about 1 month ago

What changed: The story was updated to include a new U.S. Executive Order that fast-tracks FDA approval processes for psychedelic-based mental health treatments, providing a regulatory tailwind for Clearmind.

Version 1about 1 month ago

What changed: The story was updated to include specific details regarding the number of participants (18) and the formal safety confirmation from the Data Safety Monitoring Board (DSMB).

Clearmind Medicine Inc. (Nasdaq: CMND) has reported positive safety results for its CMND-100 candidate in an FDA-approved Phase I/IIa trial for Alcohol Use Disorder (AUD), meeting all primary safety endpoints. This clinical milestone is now bolstered by a new Executive Order signed by President Trump, titled 'Accelerating Medical Treatments for Serious Mental Illness,' which prioritizes FDA review processes for psychedelic-derived treatments. The order directs the FDA to fast-track breakthrough therapy designations and expand patient access pathways for these innovative therapies. Clearmind Medicine welcomed the move as a historic catalyst for psychedelic innovation and veteran mental health care. These regulatory tailwinds, combined with successful clinical data, significantly strengthen the company's strategic position. The executive action is expected to accelerate the regulatory pathway for Clearmind’s non-hallucinogenic therapeutic pipeline.